Treat COVID-19 Patients With Regadenoson

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 6, 2021

Primary Completion Date

April 24, 2023

Study Completion Date

April 24, 2023

Conditions
COVID-19Lung Inflammation
Interventions
DRUG

Regadenoson

Regadenoson will be given intravenously as 5 ug/kg (up to 400 mg/patient) loading dose over 30 mins (to avoid unpleasant side effects sometimes associated with the rapid bolus injection of Regadenoson), followed by a continuous slow infusion (1.44micrograms/kg/hour) with the use of a pediatric infusion pump for 6 hours.

OTHER

Placebo Control

The same volume of saline will be given intravenously for 6 and half hours.

Trial Locations (1)

21201

University of Maryland Medical Center, Baltimore

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER